MetaCap

SL Science (SLBT) vs X4 Pharmaceuticals (XFOR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

X4 Pharmaceuticals (XFOR) has outperformed SL Science (SLBT) over the past year, losing 20.0% versus a loss of 94.8%. SL Science is the larger company by market cap ($308.4 million vs $306.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SLBT-94.76%XFOR-20.00%
+30%-35%-101%
Nov 21, 20251 yearNov 20, 2026
SLBT-94.51%XFOR-81.10%
+33%-34%-101%
Feb 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SLBT versus XFOR key metrics
MetricSLBTXFOR
Share price$0.55$3.00
Market cap$308.42M$306.34M
1-day change-3.36%+1.35%
YTD return-94.78%-25.00%
1-year return-94.76%-20.00%
5-year return—-97.79%
P/E ratio (TTM)—5.45
EPS (TTM)$0.00$0.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$6.50M
Revenue growth (YoY)—+150.00%
Net income (latest FY)—$-79.20M
Gross margin—11.43%
Operating margin—-1336.66%
Net margin—-1218.45%
52-week high$14.50$4.83
52-week low$0.51$2.43
Distance from 52-week high-96.21%-37.89%
Analyst consensus—strong_buy
Avg. price target upside—+286.67%
Average volume67.66K877.70K
Shares outstanding560.76M102.11M
Employees1445
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XFOR has outperformed SLBT by 74.8 percentage points over the past year.

About SL Science

SLBT stock →

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees

About X4 Pharmaceuticals

XFOR stock →

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees

SLBT vs XFOR FAQ

Which is bigger, SL Science or X4 Pharmaceuticals?

SL Science (SLBT) is larger, with a market capitalization of $308.42M compared with $306.34M for X4 Pharmaceuticals (XFOR).

Which stock has performed better over the past year, SLBT or XFOR?

XFOR returned -20.00% over the past 12 months, compared with -94.76% for SLBT (price return, excluding dividends). Past performance does not predict future results.

Are SL Science and X4 Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons